Clinical trials: Cancer, Therapy-Related
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
This is a multi-institutional phase II haploidentical T cell replete bone marrow transplant (BMT) study in children with high-risk leukemia.
- Conditions
- Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
- Trial name
- NCT02120157
- Testing
- Cyclophosphamide, TBI, Busulfan
- Where
- 9 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Lymphoma
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003114
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
HIV Infections
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
Original design: The study's purpose is to compare the effects of zidovudine (AZT) alone to the combination of AZT and acyclovir (ACV) to determine if AZT/ACV is associated with a lower death rate and fewer AIDS related…
- Trial name
- NCT00000712
- Testing
- Zidovudine, Acyclovir
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
RATIONALE: Silymarin (milk thistle extract) is an herb that may be effective in treating liver disorders caused by cancer therapy.
- Trial name
- NCT00055718
- Testing
- silymarin
- Where
- 8 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
CAYA Cancer Retrospective Cohort Study
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs).
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer
- Trial name
- NCT07246213
- Testing
- Retrospective Medical Record Review
- Where
- 7 sites in Armenia, Egypt and 4 more
- Volunteers
- 18,000 people
- Sponsor
- Resonance, Inc.
Adverse Drug Reactions, Cancer
Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
CAR-T cells and cellular therapies may lead to various adverse reactions. This study investigates reports of different toxicities for cellular therapies in the World Health Organization's (WHO) global database of individual…
- Trial name
- CARTABLE (NCT04279470)
- Testing
- CAR T-cell and Cellular Therapies
- Where
- France
- Volunteers
- 100,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Renal Cell Carcinoma, Kidney Cancer
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
- Trial name
- NCT03663946
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899652
- Testing
- Southern blotting, chromosomal translocation analysis, cytogenetic analysis
- Volunteers
- 149 people
- Sponsor
- Children's Oncology Group
Cancer, Cancer-Related Condition
Testicular Tissue Cryopreservation in Children
This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may…
- Conditions
- Cancer, Cancer-Related Condition, Infertility
- Trial name
- NCT02872532
- Testing
- Testicular tissue cryopreservation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or…
- Trial name
- NCT03827343
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Heart Failure, Cancer, Therapy-Related
Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study
Therapeutic advances have significantly improved the survival of patients with cancer. However, these novel therapies are associated with a concomitant increase in the prevalence of toxicity, including cardiovascular…
- Trial name
- NCT06268535
- Testing
- Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023
- Where
- France
- Volunteers
- 36,580,288 people
- Sponsor
- University Hospital, Caen
Cancer, Side Effect of Drug
Radiopharmaceuticals Analysis for Detailed Insights And INternational Tracking of Safety
Little is known about cancer therapy-related radiopharmaceuticals drugs safety. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of individual safety case reports, to…
- Trial name
- RADIANTS (NCT06483685)
- Testing
- Radiopharmaceuticals drugs
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- University Hospital, Caen
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neurofibromatosis Type 2, NF2
Selumetinib for NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children…
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma
- Trial name
- ASSIST (NCT07707947)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Neurofibromatosis
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that can cause frequent and significant pain. This pain can have a severe impact on a person s quality of life.
- Trial name
- NCT01633008
- Testing
- ACT Workshop
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
RATIONALE: Radioactive drugs, such as iodobenzylguanidine meta-I131, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- MIITOP (NCT00960739)
- Testing
- Topotecan hydrochloride, Autologous hematopoietic stem cell transplantation, iobenguane I 131
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret